Most frequently asked questions and answers
NervGen trades in Canada on the TSX.V under the symbol NGEN and in the U.S. on the OTCQB under the symbol NGENF.
Refer to NervGen’s latest filed financial statements for the latest available share information.
NervGen’s fiscal year end is December 31st.
NervGen’s transfer agent is:
Computershare Investor Services Inc.
510 Burrard Street, 3rd Floor
Vancouver, BC V6C 3B9
T: (604) 661-9400
NervGen’s auditor is:
KPMG LLP
Pacific Centre
777 Dunsmuir Street, P.O. Box 10426
Vancouver, BC V7Y 1K3
CUSIP #: 64082X203
ISIN #: CA64082X2032
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen is evaluating a new discovery lead, NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com